ATE169822T1 - Behandlung von herpesvirus infektion - Google Patents

Behandlung von herpesvirus infektion

Info

Publication number
ATE169822T1
ATE169822T1 AT93911414T AT93911414T ATE169822T1 AT E169822 T1 ATE169822 T1 AT E169822T1 AT 93911414 T AT93911414 T AT 93911414T AT 93911414 T AT93911414 T AT 93911414T AT E169822 T1 ATE169822 T1 AT E169822T1
Authority
AT
Austria
Prior art keywords
treatment
herpesvirus infection
herpesviruses
oligopeptide
preferred
Prior art date
Application number
AT93911414T
Other languages
English (en)
Inventor
Michael Twist
Richard W Barnett
Martin Summer-Smith
Lorne S Reid
Original Assignee
Allelix Biopharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allelix Biopharma filed Critical Allelix Biopharma
Application granted granted Critical
Publication of ATE169822T1 publication Critical patent/ATE169822T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT93911414T 1992-04-23 1993-04-21 Behandlung von herpesvirus infektion ATE169822T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87239892A 1992-04-23 1992-04-23

Publications (1)

Publication Number Publication Date
ATE169822T1 true ATE169822T1 (de) 1998-09-15

Family

ID=25359492

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93911414T ATE169822T1 (de) 1992-04-23 1993-04-21 Behandlung von herpesvirus infektion

Country Status (7)

Country Link
EP (1) EP0637247B1 (de)
JP (1) JPH08501060A (de)
AT (1) ATE169822T1 (de)
AU (1) AU4037793A (de)
CA (1) CA2134119A1 (de)
DE (1) DE69320469D1 (de)
WO (1) WO1993021941A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5633230A (en) * 1990-10-24 1997-05-27 Allelix Biopharmaceuticals, Inc. Treatment of cytomegalovirus infection
CA2152373C (en) * 1993-10-22 1998-12-15 Michael Twist (Deceased) Treatment of cytomegalovirus infection
DE19520792A1 (de) * 1995-06-07 1996-12-12 Bloch Wilhelm Dr Verwendung der Stickstoffmonoxidsynthese hemmenden Substanzen der Gruppe der L-Argininanaloge zur Herstellung eines Mittels zur Abschwellung entzündlich bzw. allergisch angeschwollener Nasenschleimhaut und der Hemmung entzündlich und allergisch bedingter Nasensekretion
ES2210761T3 (es) 1997-05-21 2004-07-01 The Board Of Trustees Of The Leland Stanford Junior University Composicion y procedimiento para mejorar el transporte a traves de las membranas biologicas.
US6919076B1 (en) 1998-01-20 2005-07-19 Pericor Science, Inc. Conjugates of agents and transglutaminase substrate linking molecules
US6958148B1 (en) 1998-01-20 2005-10-25 Pericor Science, Inc. Linkage of agents to body tissue using microparticles and transglutaminase
EP1656945A1 (de) * 1999-06-05 2006-05-17 The Board Of Trustees Of The Leland Stanford Junior University Pharmazeutische Zusammensetzung enthaltend Oligoarginin
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
WO2001013957A2 (en) 1999-08-24 2001-03-01 Cellgate, Inc. Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US7033991B2 (en) * 2001-07-16 2006-04-25 Board Of Supervisors Of Louisiana State University And Agriculture And Mechanical College Inhibiting furin with polybasic peptides
DK2178549T3 (en) * 2007-07-26 2017-01-09 Revance Therapeutics Inc Antimicrobial peptide AND COMPOSITIONS THEREOF
ES2444299B1 (es) 2012-08-23 2014-12-12 Nutrición Técnica Deportiva, S.L. Uso de un hidrolizado de caseina como agente antiherpético

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012461A1 (en) * 1988-06-16 1989-12-28 St. Louis University Antagonists of viral transactivating proteins
DK0554284T3 (da) * 1990-10-24 1997-01-06 Allelix Biopharma Peptid-baserede hæmmere af Hiv-replikation

Also Published As

Publication number Publication date
DE69320469D1 (de) 1998-09-24
WO1993021941A1 (en) 1993-11-11
CA2134119A1 (en) 1993-11-11
AU4037793A (en) 1993-11-29
EP0637247A1 (de) 1995-02-08
EP0637247B1 (de) 1998-08-19
JPH08501060A (ja) 1996-02-06

Similar Documents

Publication Publication Date Title
GR3022838T3 (en) Peptide-based inhibitors of hiv replication
DE69320469D1 (de) Behandlung von herpesvirus infektion
EA199901031A1 (ru) Производные бензимидазола
ES2075040T3 (es) 2',3'-dideoxi-2',2'-difluoronucleosidos.
MX9308016A (es) Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
DK0973735T3 (da) Polyaromatiske antivirale præparater
NO953371L (no) Anvendelse av anti-konvulsiva ved behandling av neuro-AIDS
DE69131200D1 (en) Herpes simplex virus vp16 impfstoffe
FI935172A7 (fi) Katepsiini G:n ja elastaasin inhibiittoreita sidekudoksen rappeutumise n ehkäisemistä varten
MX9308005A (es) Compuestos inhibidores de la proteasa del virus de la inmunodeficiencia humana, procedimiento para su preparacion y formulacion farmaceutica que los contiene.
MX9308025A (es) Compuestos inhibidores de la proteasa del virus dela inmunodeficiencia humana, procedimiento para supreparacion y formulacion farmaceutica que los contiene.
DE69125262D1 (de) Synergische Mischung zur Behandlung von Herpes
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
DE122005000015I1 (de) Azellul{rer Impfstoff.
DE69330268D1 (de) Hämoregulierende peptide
DE69004451D1 (de) Prophylaxe und Behandlung von Herpesvirus-Infektionen.
DE69608959D1 (de) Chlamydia impfstoffen
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
ITMI913493A1 (it) Dispositivo per la disinfezione o la immunizzazione di zone del corpo umano esposte al contagio, da germi, batteri e virus
UA41338C2 (uk) Спосіб інгібування ретровірусної інфекції, яка викликана вірусом імунодефіциту людини (віл), спосіб інгібування вірусу імунодефіциту людини (віл)
FI930519A0 (fi) Peptider foer blokering av infektioner orsakade av hiv-virus samt foerfarande foer deras anvaendnig
ATE255417T1 (de) Verwendung von bradykinin-antagonisten zur behandlung von viruserkrankungen
ATE196424T1 (de) Methode und zusammensetzung zur behandlung von herpes ähnlichen krankheiten
ES2062266T3 (es) Uso de quinolil- e isoquinoliloxazol-2-onas para la obtencion de un medicamento destinado para la prevencion de infecciones por virus envueltos por glicoproteinas.
RU93045696A (ru) Ингибиторы протеазы вируса иммунодефицита человека, полезные для лечения спида

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties